Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Fresenius Kabi AG

Division of Fresenius SE & Co. KGaA
www.fresenius-kabi.com

Latest From Fresenius Kabi AG

Strides Plans Re-Entry On Injectables

Indian firm Strides to invest up to $40m in acquired Stelis for re-entry into generic injectables and multiple biosimilar APIs as it looks to build its business.

Commercial Strategy

Strides Plans Injectables Re-entry As Mylan Non-Compete Nears End

Indian firm Strides to invest up to $40m in acquired Stelis for re-entry into generic injectables and multiple biosimilar APIs as it looks to build its business.  

Commercial Strategy

US Biosimilar Market – Who's In It For The Long Haul?

A biopharma conference in Mumbai hears how the US biosimilars landscape could potentially change over the long term when deep price cuts set in and payers have a greater say in matters. Might big pharma consider pulling out?

Commercial Strategy

Kabi Commits To Biosimilars Development

Fresenius Kabi says a research and development center that it has opened in Switzerland demonstrates its commitment to its biosimilars pipeline.

Biosimilars Research & Development
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register